TScan Therapeutics, Inc.
Canonical company identity and public leadership record.
- Source reported. 18 claims from 2 sources.
- Not claimed by the company.
- Eval: not assessed.
- Chair
- Not published
- Board
- 7 directorsAlpha calculation. Published seats
- Independence
- 6 of 7Alpha calculation
- Committees
- 2
- Evidence
- 2 sources18 published claims
- Open conflicts
- 0None open
Leadership
3 claims| Person | Role | Since | Status | Evidence |
|---|---|---|---|---|
| Chrystal Louis, M.D., M.P.H. | Chief Medical Officer | Current | Source reportedE3 | |
| Gavin MacBeath, Ph.D. | Chief Executive Officer and Director | Current | Source reportedE4 | |
| Jason A. Amello | Chief Financial Officer and Treasurer | Current | Source reportedE5 |
Board
7 claims| Director | Status | Since | Committees | Evidence |
|---|---|---|---|---|
| Barbara Klencke, M.D. | Independent | None published | Source reportedE2 | |
| Gabriela Gruia, M.D. | Independent | None published | Source reportedE2 | |
| Garry Nicholson | Independent | None published | Source reportedE2 | |
| Gavin MacBeath, Ph.D. | Not independent | None published | Source reportedE2 | |
| Katina Dorton, J.D., M.B.A. | Independent | Audit, chair; Compensation | Source reportedE2 | |
| R. Keith Woods | Independent | None published | Source reportedE2 | |
| Stephen Biggar, M.D., Ph.D. | Independent | None published | Source reportedE2 |
Committees
4 claims| Committee | Chair | Members | Risks assigned | Evidence |
|---|---|---|---|---|
| Audit | Katina Dorton, J.D., M.B.A. | Katina Dorton, J.D., M.B.A. | Not described in the published record | Source reportedE6 |
| Compensation | Not published | Katina Dorton, J.D., M.B.A. | Not described in the published record | Source reportedE6 |
| Fact | Stated value | Evidence |
|---|---|---|
| Committee appointment | Katina Dorton, J.D., M.B.A.: chair, Audit | Source reportedE6 |
| Committee appointment | Katina Dorton, J.D., M.B.A.: member, Compensation | Source reportedE6 |
Financial context
1 claim| Fact | Stated value | Evidence |
|---|---|---|
| Security listing | TCRX (NASDAQ) | Source reportedE1 |
Other published claims
3 claims| Fact | Stated value | Evidence |
|---|---|---|
| Legal name | TScan Therapeutics, Inc. | Source reportedE1 |
| Entity status | Public listing published | Source reportedE1 |
| Published fact | US | Source reportedE1 |
Evidence
6 evidence records| Ref | Source | Authority | Source date | Retrieved | Rights | Cited by |
|---|---|---|---|---|---|---|
| E1 | Alpha canonical company public projectionCanonical identity | Open web | Not recorded | Rights not recorded, link only | 4 claims | |
| E2 | TScan Therapeutics, Inc. DEF 14A 2026-04-17SEC proxy | Authoritative, regulatory filing | Rights not recorded, link only | 7 claims | ||
| E3 | TCRX DEF 14A executive officersSEC filing | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim | ||
| E4 | TCRX DEF 14A executive officersSEC filing | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim | ||
| E5 | TCRX DEF 14A executive officersSEC filing | Authoritative, regulatory filing | Rights not recorded, link only | 1 claim | ||
| E6 | Auditgovernance_people_committees. SEC proxy | Authoritative, regulatory filing | Not recorded | Not recorded | Rights not recorded, link only | 4 claims |
No evidence record is pinned or signed yet.
Not yet in this record
These parts of a company record have no published claims yet. That is a coverage state, not a finding about the company. 1 further claim is under review.
- Control and voting
- Governance
- Risk
- AI oversight
- Legal
- Compensation
Index memberships
No current membership is published in Alpha's tracked index universe.
This is not evidence that the company is absent from every market index.
As of 21 Nov 2026. Rights-filtered public evidence only; no redistribution or model training is granted. Only source-backed memberships with an explicit public redistribution basis are returned.
Coverage states the record reports (12)
- Corporate structure
- Not reviewed. Parent, subsidiary and predecessor structure explains who is governed.
- Ownership
- Not reviewed. Ownership and voting power determine who can influence the board.
- Financials
- Not reviewed. Governance-relevant financial context frames capital and audit decisions.
- Compensation
- Not reviewed. Pay design shows how incentives are governed.
- Governance
- Not reviewed. Governing documents and provisions set the rules of the enterprise.
- Shareholder governance
- Not reviewed. Meeting and vote records show shareholder dissent and support.
- Audit
- Not reviewed. Auditor, controls and restatements show assurance over reporting.
- Legal
- Not reviewed. Material legal and regulatory matters show enforcement exposure.
- Risk
- Not reviewed. Risk ownership links the board, committees, executives and controls.
- Cyber
- Not reviewed. Cyber and data governance is a disclosed oversight domain.
- AI governance
- Not reviewed. AI oversight is a differentiated Alpha governance domain.
- Markets external
- Not reviewed. Auditors, advisors, investors and regulators form the external ecosystem.
Limits of this record (5)
- Absence of a leadership role, committee, or disclosure is not evidence that it does not exist.
- Only explicitly published canonical company identity and current confirmed public roles are included.
- Absence of a board, committee, executive, listing, or claim is not evidence that it does not exist.
- Public retrieval does not grant redistribution, model-training, direct-contact, or relationship-pathfinding rights.
- This Company Profile is an identity and evidence record, not an Alpha rating.
History
Version public-1Published .
- Executive appointed. Chrystal Louis, M.D., M.P.H. executive of TScan Therapeutics, Inc., effective 17 Apr 2026.Effective . Recorded .
- CEO role recorded. Gavin MacBeath, Ph.D. executive of TScan Therapeutics, Inc., effective 17 Apr 2026.Effective . Recorded .
- CFO role recorded. Jason A. Amello executive of TScan Therapeutics, Inc., effective 17 Apr 2026.Effective . Recorded .
- Director appointed. Garry Nicholson seat on TScan Therapeutics, Inc., effective 2024.Effective . Recorded .
- Director appointed. Barbara Klencke, M.D. seat on TScan Therapeutics, Inc., effective 2023.Effective . Recorded .
- Director appointed. Gavin MacBeath, Ph.D. seat on TScan Therapeutics, Inc., effective 2023.Effective . Recorded .
- Director appointed. R. Keith Woods seat on TScan Therapeutics, Inc., effective 2023.Effective . Recorded .
- Director appointed. Gabriela Gruia, M.D. seat on TScan Therapeutics, Inc., effective 2021.Effective . Recorded .
- Director appointed. Katina Dorton, J.D., M.B.A. seat on TScan Therapeutics, Inc., effective 2021.Effective . Recorded .
- Director appointed. Stephen Biggar, M.D., Ph.D. seat on TScan Therapeutics, Inc., effective 2021.Effective . Recorded .
About this record
- Alpha ID
- alpha:company:c001ee25-e24f-4289-adc1-209bf72a5d3b
- Version
- public-1:ro-d751713988987e9331980363e24189ce
- Identity
- Not claimed
- Evidence
- Source reported
- Evaluation
- Not assessed
- Monitoring
- Not monitored yet
- Authority
- Not published
- Freshness
- Current
- Integrity
- Not signed yet
- Basis
- Published company record built from public sources
- Never published
- Private company data: deployments, authority grants, TrustChecks, receipts, telemetry
The company can claim this record and correct or dispute any claim. Corrections are versioned and the original stays in history. A company's own statements are shown as its own and never replace the cited evidence.

